This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
The internal validity of the primary studies was high in the case of clinical trials. However, the robustness of the other sources was not discussed.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Twenty primary studies provided clinical data.
Methods of combining primary studies
The primary data derived from the 8 clinical trials were not combined. Other clinical data were entered into the decision model in a narrative way.
The frequency of ICD generator replacement was 5 years (range: 2 -9).
The probability of lead problems requiring surgical intervention was 2.4% (range: 0 -5).
The utility value associated with control therapy was 0.88 (range: 0.6 -1).
The all-cause mortality rate was not reported.
Methods used to derive estimates of effectiveness
The authors made some assumptions that were used in the decision model.
Estimates of effectiveness and key assumptions
The duration of ICD benefit was assumed to have been lifetime.
The utility value associated with the ICD was 0.88 (range: 0.6 -1).
The quality of life decrements due to hospitalisation for lead infections were 3.5 days.
Measure of benefits used in the economic analysis
The summary benefit measures used were the life-years (LYs) gained and quality-adjusted life-years (QALYs). These were estimated using the decision model. The source of the utility values, which were combined with expected survival in order to calculate the QALYs, was reported. However, no details of the methods used to elicit patient preferences were given. An annual discount rate of 3% was applied to the benefit measures.
Direct costs
of the ICD in reducing mortality, the cost of ICD implantation, the frequency of generator replacement, quality of life and the time horizon. A univariate sensitivity analysis appears to have been used. The ranges of values used were derived from confidence intervals given in the literature and on the basis of the authors' judgement.
Estimated benefits used in the economic analysis
In six of the eight populations, implantation of the ICD improved life expectancy relative to control therapy. The discounted increment ranged from 1.40 to 4.14 years (undiscounted range: 2.12 -6.21) or from 1.01 to 2.99 QALY (undiscounted range: 1.53 -4.47). In the other two populations (based on the DINAMIT and CABG Patch trials), the life expectancy of patients that received the ICD was lower than that of the control group.
Cost results
Independent of the patient population, the ICD was more expensive than the control therapy. The increase in the estimated lifetime discounted costs ranged from $55,700 in the CABG Patch Trial to $101,500 in the MUSTT.
Synthesis of costs and benefits
Incremental cost-effectiveness ratios (cost per LY saved) and cost-utility ratios (cost per QALY gained) were calculated to combine the costs and benefits of the ICD over control therapy.
In six of the eight populations, the incremental cost-effectiveness ratios ranged from $24,500 (MUSTT) to $50,700 (SCD-HeFT) while the incremental cost-utility ratio ranged from $34,000 (MUSTT) to $70,200 (SCD-HeFT).
In two trials (DINAMIT and CABG Patch), the life expectancy of the patients who received an ICD was less than that of the patients who received control therapy. Thus the ICD was both more expensive and less effective than control therapy, which was the dominant strategy.
The sensitivity analysis showed that the incremental cost-effectiveness of the ICD tended to be more favourable in higher risk patients, given that the efficacy of an ICD is related to the annual mortality rate in the patient population. Similarly, the cost-effectiveness of the ICD improved with reductions in the cost of the device. For example, if the cost of an ICD was reduced to $10,000 ($27,975 in the base-case), the incremental cost per QALY decreased to $27,900 for the MUSTT (minimum) and to $52,400 for the SCD-HeFT. On the other hand, the incremental cost-effectiveness of the ICD was less favourable as the frequency of replacement increased (replacement every 3 years led to an incremental cost per QALY of $41,200 to $88,600).
If the patients' quality of life was decreased by prophylactic ICD implantation, the cost-effectiveness of this approach would have been much less favourable.
In the clinical trials in which prophylactic implantation of an ICD was found to be better than control therapy, a reduction in the patients' utility on the basis of the presence of left ventricular dysfunction resulted in a costeffectiveness of the ICD of $39,800 to $82,400 per QALY gained.
When keeping a lifelong horizon but assuming that ICD efficacy ceases after the first 3 years, the cost-effectiveness of the ICD was much less favourable in comparison with the control treatment, ranging from $70,200 per QALY gained in the MUSTT to $171,800 per QALY gained in the SCD-HeFT.
The cost-effectiveness became substantially more favourable as the time horizon increased.
Authors' conclusions
Compared with control therapy, the implantable cardioverter-defibrillator (ICD) had a cost-effectiveness ratio below $100,000 per quality-adjusted life-year (QALY) gained in populations in which a significant device-related reduction in mortality had been demonstrated. However, the authors stated that the prophylactic implantation of an ICD might not be feasible for health policy-makers, owing to the high cost of the device and the large patient population in which it could be applied.
